Discriminating Established Cardiovascular Disease Using a Novel Multiterritory Ultrasound Plaque Burden Measure (wTPT): Findings From the P-SONAR Study
Discuss this preprint
Start a discussion What are Sciety discussions?Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Objective Ultrasound-imaging of subclinical atherosclerosis may refine cardiovascular (CV) risk assessment, but quantification methods vary and often include carotid arteries only. Because atherosclerosis is multiterritory, global (carotid–femoral) plaque quantification may better reflect systemic burden. We examined whether a novel multiterritory measure, weighted total plaque thickness (wTPT), better discriminates established CV disease than traditional risk factors and plaque measures. Methods In 5 418 participants (59.8 ± 8.1 years; 53.0% women) from the Prospective Screening Of Non-invasive Atherosclerosis Risk study, plaque burden was assessed across 12 carotid and femoral segments using wTPT, maximal plaque thickness (MPT), plaque count, and number of arteries with plaque. Discrimination of prior CV disease was evaluated using c-statistics, net reclassification improvement (NRI), and integrated discrimination improvement (IDI). Results Global wTPT showed the strongest discrimination of established CV disease (c-statistic 0.85 [95% CI: 0.83–0.87]), outperforming alternative plaque measures (p < 0.001). Adding global wTPT to risk factors improved discrimination from 0.84 to 0.89 (95% CI: 0.87–0.91), NRI 0.71 (95% CI: 0.57–0.84) and IDI 0.058 (95% CI: 0.004–0.071). Femoral wTPT outperformed carotid wTPT (p < 0.001), and global wTPT exceeded both (p = 0.014). Across wTPT quartiles, odds of prior CV disease increased stepwise: 2.0 (95% CI: 0.89–4.4), 4.2 (95% CI: 2.0–8.6), and 10.0 (95% CI: 5.0–20.1) versus the lowest quartile. Conclusion Global wTPT showed superior discrimination of established CV disease and added substantial predictive information beyond standard risk factors. These findings support wTPT as a marker of systemic atherosclerosis and a strong candidate for outcome-based risk refinement. Trial registration clinicaltrials.gov. Identifier: NCT06933745. Registered 22 april 2025